Literature DB >> 18265888

Antiepileptogenesis Therapy with Levetiracetam: Data from Kindling versus Status Epilepticus Models.

F Edward Dudek, Edward H Bertram, Kevin J Staley.   

Abstract

Entities:  

Year:  2008        PMID： 18265888      PMCID： PMC2238642          DOI： 10.1111/j.1535-7511.2007.00226.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  5 in total

1.  Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.

Authors:  N R Temkin
Journal:  Epilepsia       Date:  2001-04       Impact factor: 5.864

2.  Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.

Authors:  W Löscher; D Hönack; C Rundfeldt
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

3.  Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols.

Authors:  Heidi L Grabenstatter; Suzanne Clark; F Edward Dudek
Journal:  Epilepsia       Date:  2007-08-17       Impact factor: 5.864

4.  Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats.

Authors:  Claudia Brandt; Maike Glien; Alexandra M Gastens; Maren Fedrowitz; Kerstin Bethmann; Holger A Volk; Heidrun Potschka; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2007-05-18       Impact factor: 5.250

Review 5.  The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy.

Authors:  Wolfgang Löscher
Journal:  Epilepsia       Date:  2007-04-18       Impact factor: 5.864
  5 in total
  8 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Levitating levetiracetam's status for status epilepticus.

Authors:  Lawrence J Hirsch
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

Review 3.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

Review 4.  Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis.

Authors:  Caren Armstrong; Robert J Morgan; Ivan Soltesz
Journal:  Epilepsia       Date:  2009-07-01       Impact factor: 5.864

Review 5.  Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions.

Authors:  Doodipala Samba Reddy; Ramkumar Kuruba
Journal:  Int J Mol Sci       Date:  2013-09-05       Impact factor: 5.923

Review 6.  Statins as antiepileptogenic drugs: Analyzing the evidence and identifying the most promising statin.

Authors:  Yousif Hufthy; Mahima Bharadwaj; Shubhi Gupta; Delwar Hussain; Prince Josiah Sajanthan Joseph; Alizah Khan; Jessica King; Pieter Lahorgue; Ovin Jayawardena; Danial Rostami-Hochaghan; Chloe Smith; Anthony Marson; Nasir Mirza
Journal:  Epilepsia       Date:  2022-06-10       Impact factor: 6.740

7.  Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.

Authors:  Carol M Ulloa; Allen Towfigh; Joseph Safdieh
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

Review 8.  Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.

Authors:  Wolfgang Löscher; Michel Gillard; Zara A Sands; Rafal M Kaminski; Henrik Klitgaard
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.